OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

Dr. Tap on Future Research Efforts in Sarcoma

November 4th 2020

William D. Tap, MD, discusses future research efforts in sarcoma.

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Dr. Bekaii-Saab on the Future of Telemedicine in CRC

November 4th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

Dr. Beltran on the Need to Identify Non–AR Targets in Prostate Cancer

November 3rd 2020

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Dr. Vorobiof on Financial Toxicity in Oncology

November 3rd 2020

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Dr. Lonial on the Role of BCMA in Multiple Myeloma

November 2nd 2020

Sagar Lonial, MD, FACP, discusses the role of BCMA as a target in multiple myeloma.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Dr. Mahal on the Prevalence of Prostate Cancer in African American Men

November 2nd 2020

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men.

Dr. Salani on Therapeutic Advances in Endometrial Cancer

November 2nd 2020

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma

November 2nd 2020

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

November 2nd 2020

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

October 30th 2020

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Dr. Ahn on the Identification of NTRK Alterations in CRC

October 30th 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the importance of community and academic collaboration in sarcoma.

Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

October 29th 2020

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer

October 29th 2020

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.